At Medrio, we believe that clinical trial technology shouldn’t be difficult to use. That’s why our full-service eClinical Data Management suite helps streamline your research and unify your solutions so you have more time to focus on your patients, rather than multiple vendors. Since 2005, our flexible technology has evolved alongside our customers to include an integrated suite of EDC, DDC, eConsent, RTSM, and ePRO/eCOA solutions that support your teams and sites, while reducing patient burden.
Let our solutions put you back in the driver’s seat with adaptive technology that easily powers mid-study changes and accelerates your trials, without compromising data quality. Or lean on our global team of experts who are available 24/7 to support you where you need it most. We’ve worked alongside Sponsors, CROs, and sites—spanning all therapeutic areas and trial phases—to secure over 375 approvals because we know it takes a village to achieve a healthier world.



  • Australia and New Zealand have not been impacted as much as North America and the EU with regards to COVID-19. For this reason, and their quick study-start timelines, this region could become very attractive to sponsors in the near future. In this podcast, Yvonne Lungershausen and Sandrien Louwaars discuss how Avance Clinical prepared for the pandemic, what tools they implemented that allowed trial continuation, and why clinical trials are currently thriving in the region.

  • Hope Biosciences focuses on stem-cell research to prevent disease and degeneration. In this podcast, the CEO of Hope Biosciences discusses the recent advances in stem-cell research, the potential stem-cells have for curing disease, and what she believes the future may hold. We’ll also discuss Hope Bio’s current COVID-19 trial and how stem-cell therapies are playing their part to combat this global pandemic.

  • Constantly changing regulations and a multitude of new endpoints continue to keep clinical researchers on their toes. While these regulations and endpoints are designed to keep patients safe, they often create unintended barriers that keep patients out of clinical trials. In this episode, we discuss with Kafayat Babajide, Director of Patient Insights & Experience with Johnson and Johnson, the ways in which a patient-centric approach can remove controllable barriers from the clinical trial process and strengthen your patient engagement.

  • Due to COVID-19 the clinical trial industry has been adopting advanced clinical trial technology at warp speed, but what does this mean for the future? What is a sustainable approach to ensure the industry does not face the same challenges and delays should we be impacted by another pandemic or global crisis? In this podcast we sit down with Mary Mattes, Senior Vice President of Global Operations at Synteract to discuss decentralization of clinical trials and a hybrid model. 

  • Quartesian and Medrio have had a solid partnership since 2010 and have partnered together in over 250 studies. In this podcast, we’ll discuss the foundation of our successful partnership, eSource, and the innovative ways we are collaborating with Quartesian on a COVID-19 study currently underway.

  • Phastar and Medrio have been partnering together on trials for the past 3 years, culminating in a unique way to visualize clinical trial data. Through the use of Medrio’s API, Phastar has built a data visualization tool that reduces risk and allows for complete study oversight. In this podcast we’ll discuss the need for data visualization in clinical trials, how Phastar has continued their trials during a global pandemic, and what their thoughts are on the future of how we collect and view data.

  • Patients are no longer passive research subjects, but rather being integrated into the research process from the start. Advocating for a patient is advocating for a human being, not a test subject. As clinical research evolves more emphasis has been placed on patient experience, rather than just data points.

  • Reducing the number of vendors you interact with allows you to not only achieve higher quality data, you can also spend more time focusing on what matters- the patients. Our fully integrated RTSM and EDC allows you to spend more time focused on your data and less on outside programmers and vendors. In this episode we will explore the value of a combined solution and what you can expect in return.

  • Approximately 39.5% of all men and women will be diagnosed with cancer at some point during their lifetimes, and yet only 8% of oncology patients participate in clinical trials. Many industry leaders think that a greater focus on patient advocacy could be the missing link. In this podcast, Rose Gerber, Director of Patient Advocacy and Education at the Community Oncology Alliance – once a patient herself and now a dedicated advocate – will share her story and discuss how patient advocacy is helping to increase patient enrollment in clinical trials across every therapeutic area.




345 California Street, Suite 325

San Francisco, CA 94104


Phone: (415) 963-3700

Contact: Jillian Tygh


  • What steps can sponsors and CROs take to position their early-stage studies for success and expedite their final market approval? In this article, we’ll explore three obstacles that researchers face early in phase I studies, as well as some insight into how the right eClinical suite can overcome those challenges.

  • Planned and unplanned mid-study changes add an average of 30 days to clinical trial timelines, according to a new study by the Tufts Center for the Study of Drug Development (CSDD). This blog highlights more findings from this survey and expert insights on how to overcome the challenges of mid-study changes.

  • Traditional clinical trial models place limitations on patients, with logistical and geographic barriers making it difficult to recruit, enroll, and retain a diverse participant pool. Decentralized clinical trials bring the study to the patient, in some cases virtually, reducing timelines, increasing patient engagement, and optimizing efficiency with new technology. We sat down with Dr. Bola Oyegunwa, Vice President and Head of Virtual Trials at Covance at a recent webinar. In this Q&A he shares his direct experience in implementing decentralized trials and provides guidance on how to get started.

  • As the clinical trial industry focuses on finding a “new normal” during the COVID-19 pandemic, we are focused on how Medrio can assist in your trials now, when remote services are needed more than ever. Paper studies are at a stand-still and that’s leaving sponsors, CRO’s and sites scrambling to find a path forward.

  • The modern and highly regulated clinical trial industry has never faced a pandemic of this magnitude, and trial continuation is critical when patients’ lives are in the balance. The FDA has approved and encouraged the use of eSource since 2013, but some were still resistant to adopting virtual protocols. Will COVID-19 be the catalyst to following the FDA guidelines on decentralized and virtual trials?

  • At the onset of COVID-19, we began an impact survey to gauge how sponsors and CROs were reacting to the pandemic and how their trials were being affected. WE learned that studies that adopted ePRO prior to COVID-19 have been showing fewer delays than paper-based studies. This blog explores how ePRO is helping keep studies on track.

  • With an industry average of 12 weeks, it’s incredible that we enabled Cytovale, Inc. to achieve their first patient in (FPI) in just seven days. In a time where speed is of the utmost importance, Medrio supported Study Builders, LLC to build the study and Cytovale to begin enrolling patients in the study in just seven days. The Cytovale technology will allow patients with sepsis to be identified earlier in their hospital stay.

  • Medi-Tate Ltd., a medical device company based in Israel, was regularly using a paper-based process for collecting and managing data in clinical studies of its flagship product, the iTind system for treatment of BPH. By choosing Medrio as their introduction to EDC, they were able to take advantage of rapid study build functionality, remote monitoring capabilities, and top-tier training and support.

  • In a recent rescue study, Resolutum Global, a contract research organization, faced the challenge of building a hybrid paper/EDC solution for an ongoing study that the previous provider had conducted on paper over 4 years. By leveraging Medrio, they were able to succeed in this task and deliver satisfaction to the study sponsor.

  • Patient data has become more valuable and vulnerable as the technology used to store it – EDC, EHRs, and other systems – outpaces the regulations designed to protect it. Having a fully compliant, robust EDC is essential to ensuring that regardless of how you facilitate your trial, your data is always accurate, compliant, and secure. Here are some guiding principles to ensure data security for EDC software.

  • You may be thinking that virtual and decentralized are one and the same, but I believe the definitions are a bit more fluid. While the terms virtual and decentralized have been used synonymously, hybrid trials have also been described as a decentralized trial. In this blog we explain these terms and what they mean for the patient, researcher, clinician.

  • Informed consent is critical to every clinical trial, but often a daunting process from the patient perspective. This blog explores how the patient feels more in control of their consenting process with eConsent over the paper process.

  • Trial drop-out rates continue to increase and some clinical trials grind to a halt due to low recruitment and retention rates. Could both be avoided by engaging a patient advocate early on to set patient expectations and allow sponsors to see the trial from a new perspective?

  • We’ve all had to make adjustments to our protocols in light of social distancing requirements and to keep patient safety paramount. But thankfully, we have the tools to do that. Using these existing tools while also changing our study design have allowed us to keep our trials moving during the pandemic. As a side benefit, we’ll also likely add to the geographical diversity of our patient participants in the future and ideally include previously underrepresented groups.